Coma

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

Retrieved on: 
Wednesday, February 14, 2024
Blood, United States patent law, Friction, Coma, Risk, Physician, Unitary state, Patent, Annual report, ART, Patient, OXY, HYLA, Intubation, Human, Immune system

RA'ANANA, Israel, Feb. 14, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART500 device. This innovation has 16 claims found to be novel.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART500 device.
  • The orbiting blood oxygenation delivery system (VORTX™) is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape.
  • The current fiber technologies used for blood oxygenation cause substantial damage to the patient's blood cells.
  • We believe that the orbiting blood oxygenation delivery system is another potentially game-changing core technology of the INSPIRA ART500 device, in targeting the $19 billion mechanical ventilation market.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Anxiety, Paranoia, Coma, Somatic symptom disorder, Substance abuse, ACI, FDA, United States Adopted Name, Psychosis, CNS, Patient, Medication, Cannabis, Seizure, Depression, Pharmaceutical industry

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2023, and recent updates.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2023, and recent updates.
  • Second Quarter Fiscal Year 2024 and Subsequent Highlights:
    “Anebulo continues to make progress towards our goal of becoming the first company to have an approved treatment for acute cannabinoid intoxication.
  • “We are pleased to report that the USAN Council has adopted selonabant as the generic name for ANEB-001.
  • Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

Santé's Expert Commentary on the Danger of Tianeptine or "Gas Station Heroin"

Retrieved on: 
Monday, February 12, 2024
Elixir, Anxiety, Opioid use disorder, Heroin, Coma, Xerostomia, Medical director, FDA, Food, Pain, Thought, Somnolence, Nausea, Confusion, Letter, Risk, Safety, History, Death, Agitation, Nightmare, Consciousness, Arrhythmia, Seizure, Depression, Dietary supplement

ARGYLE, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- The U.S. Food and Drug Administration (FDA) recently issued a new and urgent warning about using any products, such as Neptune's Fix, that contain tianeptine. They sent a letter on January 11, 2024 to convenience stores, gas stations, vape/smoke shops and other companies advising the retailers to stop selling any tianeptine-containing products. In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.

Key Points: 
  • In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.
  • There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.
  • In fact, tianeptine products are being touted "with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.
  • "³
    "There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.

Locked-in syndrome is predominant outcome when children survive drowning, larger study confirms

Retrieved on: 
Friday, January 26, 2024
Code, Learning, Patient, Caregiver, University of Texas System, Research, MRI, Neurology, Intubation, MD, Health, SAN, Pediatric Neurology, School, Perception, Survivor, University, Medicine, Public, Radiology, Disability, Dentistry, Drowning, Family, Fox, Locked-in syndrome, Cognition, Child, Coma, Physician, Magnetic resonance imaging, Emotion, Nursing, Parent, Brain, Teaching

SAN ANTONIO, Texas, Jan. 25, 2024 /PRNewswire-PRWeb/ -- It is a far cry from the traditionally thought-of "vegetative state" in which the mind is absent while the body lives on. Indeed, it is the opposite. Children with "locked-in syndrome," unable to move or speak, are awake and fully aware of their surroundings.

Key Points: 
  • Children with "locked-in syndrome," unable to move or speak, are awake and fully aware of their surroundings.
  • Now, in follow-up research published in the journal Pediatric Neurology, the team reports the largest study to date on the subject.
  • The recently published analysis of 154 children confirms that the predominant outcome of non-fatal pediatric drowning is locked-in syndrome.
  • In the research, 60% of children who survived drowning events (93 of 154) were classified as locked in by family caregivers surveyed by UT Health San Antonio.

Household Income and Health Insurance Among Factors in Decision to Withdraw Life Support After Hemorrhagic Stroke

Retrieved on: 
Thursday, January 18, 2024
Koto, Stroke, Death, Roger Hawkins (drummer), Patient, NYU Langone Health, Research, Medicaid, Bleeding, RN, BSN, Health, Intraparenchymal hemorrhage, Medicare, Rehabilitation, Religion, NYU, MSN, Neurosurgery, Coma, Neurology, Blood, Catholic Church, Brain, Intracerebral hemorrhage, Physician, Pharmaceutical industry

Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.

Key Points: 
  • Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.
  • By contrast, being Black and having private insurance were factors tied to a lower likelihood of life support being withdrawn.
  • Among hospitalized hemorrhagic stroke patients, Blacks made up 7% of those who had life support withdrawn but counted for 18% of those who maintained life support.
  • Similarly, while 37% had private health insurance, only 20% of those who decided to withdraw life support had private insurance.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
Thursday, January 4, 2024
Coma, Urine, Hepatic encephalopathy, Ascites, Kidney, Oliguria, Physician, Benign prostatic hyperplasia, Blood volume, Uric acid, Organic acid, Anuria, Urinary retention, NYHA, Furosemide, Cerebral edema, Hypersensitivity, Diuresis, Thrombosis, Deafness, Glucose, Azotemia, Ototoxicity, Creatinine, Tinnitus, Traction, BUN, Hypoproteinemia, Edema, Growth, Investment, Congestion, Huber loss, Patient, Bruise, Dehydration, CO2, Heart failure, Cirrhosis, Embolism, History, Erythema, Pharmaceutical industry

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

Healed Warrior Uses His Story to Inspire Others

Retrieved on: 
Wednesday, November 22, 2023
Well, Brooke Army Medical Center, Coma, Fisher House, Walking, Injury, Family, Intrepid, Divorce, Burn, Army, Defense, Hatboro, Pennsylvania, Amputation, PTSD, Privacy, Spine, Sleep, Face, Pelvis, IED

And then they finally were able to release me from the hospital and allow me to start at the Center for the Intrepid.

Key Points: 
  • And then they finally were able to release me from the hospital and allow me to start at the Center for the Intrepid.
  • That's for sure.”
    J.P. and his wife, Crystal, now spend their time traveling and telling his story to inspire others.
  • I am literally a walking example of being able to do so much.”
    “I'm not a wounded warrior.
  • I'm just a warrior, because I'm healed, and I'm even stronger than I used to be.

iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Research, Safety, Nerve, CTN, Gene editing, Ornithine transcarbamylase deficiency, Pediatrics, Gene, University, Coma, Mouse, Liver, Clinical trial, Disease, Risk, TGA, Patient, GTP, Nervous system, Pharmacokinetics, Child, Blood, Primate, Trial of the century, Ammonia, Death, Metabolic disorder, Neurology, Quality of life, OTC, Mount Sinai Hospital (Manhattan), Pharmaceutical industry, Dietary supplement, Medicine

“The TGA’s clearance to begin clinical trials for the OTC-HOPE study represents major milestones for the OTC deficiency community and for the iECURE team,” said Joe Truitt, Chief Executive Officer of iECURE.

Key Points: 
  • “The TGA’s clearance to begin clinical trials for the OTC-HOPE study represents major milestones for the OTC deficiency community and for the iECURE team,” said Joe Truitt, Chief Executive Officer of iECURE.
  • “ECUR-506 has the potential to restore the function of the OTC enzyme in infants who lack this critical component of the urea cycle.
  • We are hopeful that our approach will be a better option for these children.”
    The OTC-HOPE study is a Phase 1/2 first-in-human study in baby boys with genetically confirmed neonatal-onset OTC deficiency.
  • Currently available medical therapies do not correct the disease and do not eliminate the risk of life-threatening symptoms or crises.

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

Retrieved on: 
Wednesday, December 13, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Precision BioSciences, Nerve, Gene editing, Ornithine transcarbamylase deficiency, HDR, Gene, Clinical trial, Coma, IND, Liver, Disease, Risk, Patient, Cell, ESGCT, Blood, Hepatocyte, Primate, CRISPR, Ammonia, Death, Neurology, Congress, CTA, OTC, Precision, Metabolic disorder, Vaccine

“The acceptance of iECURE’s Clinical Trial Application marks an important milestone for patients with OTC deficiency and for both the iECURE and Precision BioSciences teams.

Key Points: 
  • “The acceptance of iECURE’s Clinical Trial Application marks an important milestone for patients with OTC deficiency and for both the iECURE and Precision BioSciences teams.
  • This is the first ARCUS in vivo gene editing program to progress into the clinic,” said Michael Amoroso, Chief Executive Officer of Precision Biosciences.
  • A 5% threshold of enzymatic activity has the potential for clinical benefit as previously identified in Annals of Clinical and Translational Neurology .
  • “ECUR-506 is the first of several partnered and wholly owned gene editing programs leveraging ARCUS in differentiated indications and we look forward to initial clinical data from this program.”

Drive Safely on Washington Roads this Holiday Season

Retrieved on: 
Wednesday, December 13, 2023
Law enforcement, Life, Risk, Head, Multimedia, Crash, Fatality, Judgement, WTSC, Public policy, Accident, Coma, Road, Ridesharing, Liquor, Washingtonian movement

OLYMPIA, Wash., Dec. 12, 2023 /PRNewswire-PRWeb/ -- The Washington Traffic Safety Commission (WTSC) is asking Washingtonians to have a happy holiday season by travelling safely and responsibly on all roads and highways.

Key Points: 
  • OLYMPIA, Wash., Dec. 12, 2023 /PRNewswire-PRWeb/ -- The Washington Traffic Safety Commission (WTSC) is asking Washingtonians to have a happy holiday season by travelling safely and responsibly on all roads and highways.
  • Law enforcement agencies across the state will have an increased presence on roads over a period from December 13 to January 1 to help remind everyone to drive safely.
  • Last year, 740 people died on Washington roads, with more than half of those fatalities involving alcohol or drug impaired driving.
  • "Most people drive sober, but the small number of people who drive impaired pose a serious risk to themselves and to all of us on our roads," said Mark McKechnie, WTSC External Relations Director.